{"database": "openregs", "table": "documents", "rows": [["FDA-2021-D-0691-0002", "FDA", "FDA-2021-D-0691", "Pharmacokinetic-Based Criteria for  Supporting Alternative Dosing  Regimens of Programmed Cell  Death Receptor-1 (PD-1) or  Programmed Cell Death-Ligand 1 \n(PD-L1) Blocking Antibodies for  Treatment of Patients with Cancer Guidance for Industry DRAFT GUIDANCE", "Other", "Guidance", "2021-08-26T04:00:00Z", 2021, 8, "2021-08-26T04:00:00Z", null, "2022-12-02T13:26:12Z", null, 0, 0, "0900006484ca880e"]], "columns": ["id", "agency_id", "docket_id", "title", "document_type", "subtype", "posted_date", "posted_year", "posted_month", "comment_start_date", "comment_end_date", "last_modified", "fr_doc_num", "open_for_comment", "withdrawn", "object_id"], "primary_keys": ["id"], "primary_key_values": ["FDA-2021-D-0691-0002"], "units": {}, "query_ms": 0.31188002321869135, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}